- Patent Title: Human neutralizing antibodies binding to influenza neuraminidase
-
Application No.: US15548919Application Date: 2016-02-04
-
Publication No.: US10174127B2Publication Date: 2019-01-08
- Inventor: Miriam Verena Bujny , Remko Van Der Vlugt
- Applicant: Janssen Vaccines & Prevention B.V.
- Applicant Address: NL Leiden
- Assignee: Janssen Vaccines & Prevention B.V.
- Current Assignee: Janssen Vaccines & Prevention B.V.
- Current Assignee Address: NL Leiden
- Agency: Panitch Schwarze Belisario & Nadel LLP
- Priority: EP15153891 20150205
- International Application: PCT/EP2016/052363 WO 20160204
- International Announcement: WO2016/124682 WO 20160811
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/395 ; C07K16/28 ; A61K39/12 ; A61K39/145 ; C07K16/40 ; C07K16/10 ; G01N33/569

Abstract:
The present invention provides influenza neuraminidase (NA)-binding human antibodies, which are capable of neutralizing at least one influenza A virus strain comprising NA of the N1 subtype, and antigen-binding fragments thereof. In certain embodiments, the antibodies or antigen-binding fragments furthermore are capable of neutralizing at least one influenza A virus strain comprising NA of the N2 subtype. The invention furthermore relates to the use of said antibodies or antigen-binding fragments in the diagnosis, prophylaxis and/or treatment of influenza infection.
Public/Granted literature
- US20180016348A1 HUMAN NEUTRALIZING ANTIBODIES BINDING TO INFLUENZA NEURAMINIDASE Public/Granted day:2018-01-18
Information query